Solifenacin demonstrates high absolute bioavailability in healthy men

Drugs in R and D

Volumn 5, Issue 2, 2004, Pages 73-81

  Kuipers, Mirjam E ^a   Krauwinkel, Walter J J ^a   Mulder, Hans ^a   Visser, Nico ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; HEPARINOID; KETOCONAZOLE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; HEADACHE; HERNIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OVERACTIVE BLADDER; PERSONALITY DISORDER; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; URINARY EXCRETION;

ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES;

EID: 2342663710     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405020-00002     Document Type: Article

References (17)

1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Wyndaele JJ. The overactive bladder. BJU Int 2001; 88: 135-40
3. Stewart W, Herzog R, Wein A, et al. The prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001; 20: 406-8
4. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6: S565-73
5. Abrams P, Kelleher CJ, Kerr L, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 Suppl. 11: S580-90
6. Cardozo L, Kuzmin I, Lisec ML, et al. YM905 in symptomatic overactive bladder: results of a Phase 3A randomised, placebo-controlled trial [abstract]. J Urol 2003; 169 Suppl. 4: 350
7. Chapple CR, Araño P, Bosch JLHR, et al. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase II, dose-finding study [abstract]. Neurourol Urodyn 2002; 21: 381-2
8. Smith N, Grimes I, Ridge S, et al. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30: Heidelberg. Heidelberg: ICS 2002
9. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103
10. Smulders RA, Krauwinkel W, Abila B, et al. 10- and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic: pharmacokinetics, pharmacodynamic, and safety in healthy, elderly men and women [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30: Heidelberg. Heidelberg: ICS 2002
11. Smith N, van Zijtfeld J, Swart PJ. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905 [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30: Heidelberg. Heidelberg: ICS 2002
12. Smulders RA, Tan HT, Krauwinkel W, et al. A placebo-controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905 [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30: Heidelberg. Heidelberg: ICS 2002
13. Smulders RA, van Alphen WW, Visser JN, et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30: Heidelberg. Heidelberg: ICS 2002
14. Uchida T, Smulders RA, Abila B, et al. Pharmacokinetics of YM905, a novel, bladder-selective antimuscarinic, are not adversely affected by food [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30: Heidelberg. Heidelberg: ICS 2002
15. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515-20
16. Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-95
17. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001; 40: 227-35